药物性肝损伤的基因多态性与中医诊疗研究进展

打开文本图片集

【中图分类号】R259 【文献标志码】A 【文章编号】1007－8517（2026）05-0068-06

DOI：10. 3969/j. issn. 1007 -8517. 2026. 05. zgmzmjyyz202603014

Research Progress of Gene Polymorphism and Diagnosis／Treatment in Drug- Induced Liver Injury

LIU Yuan1 XI Feiyan1 MA Yifeng1 GUO Xiaojia²

1.Lanzhou Pulmonary Hospital，Lanzhou730046，China；2.Lanzhou UniversitySecond Hospital，Lanzhou 730030，China

Abstract：Theliveristhemainorganthatmetabolizesdrugsoritsmetabolitesinthebody.Whentheexposuresexceedsthemetaboliccapacityoftheliver，itcanleadtoepatocytedamageandiitiateinherentoadaptiveimmuneresposeswithabnoalfliver biochemicalindicators，cholestasis，acuteliverfilureandothersymptoms.Atpresent，Itwaspaidcloseatentiontotheassociation betweendrug metabolicenzymes，humanleukocyteantigens，ATPtransportersanddrug-inducedliver injury.Thisarticlesummarizedtheefectsof lverfunctinbyteaforementioediologicalfctorsduringdrugmetabolismandthelatestreseachprogessonthe diagnosisandtreatmentILI.AimedtodiscovermoreriskfactorscandirectlyorindirectlyinduceDLI，andprovidessupportforthe earlywarning，diagnosis，treatment，prognosis，and new drug development of DILI.

Key Words： Drug Induced liver Injury；Gene Polymorphism； Drug Metabolic Enzymes；TCM Treatment

药物性肝损伤（drug-induced liverinjury，DILI）是指由化学药品、生物制品、中成药等上市药品，以及中药材、天然药物、保健品、膳食补充剂等产品或其代谢产物乃至其辅料、污染物、杂质等所致的肝损伤，根据临床表现其归属中医的“黄疸”“胁痛”“虚劳”“痞满”等疾病范畴。（剩余13962字）